Followup on the "Ashley Treatment": Growth Attenuation and Ethics Presentation
The following presentation is a followup to "the Ashley Treatment," for which DRW released its investigative report in May 2007. For more information, go to Ashley Treatment Investigation. DRW did not organize the following forum, but advocates and the public are welcome to attend.
Evaluating Growth Attenuation in Children with Profound Disabilities: Interests of the Child, Family Decision-Making and Community Concerns
A public presentation and discussion with the Seattle Growth Attenuation and Ethics Working Group
Friday, January 23, 2009
1:00 - 4:00 pm reception to follow
Magnuson-Jackson Moot Court Room (138)
William H. Gates Hall, University of Washington
The story of "Ashley", a six-year-old girl with profound developmental disabilities, became national news in 2007 when her parents requested that doctors use estrogen to limit her final adult height to 4'6'. Her story sparked a heated public debate regarding the child's interests, the societal implications, resource allocation and parental decision-making.
With support from the Simpson Center for the Humanities and the Greeenwall Foundation, the Treuman Katz Center for Pediatric Bioethics at Seattle Children's convened a twenty-person, interdisciplinary working group to explore these deep ethical issues. The group has produced a draft report identifying areas of common ground and points of disagreement in order to facilitate further dialogue.
Come hear and discuss the findings with the Working Group Organizers.
For more information and to register for this free event, visit: http://bioethics.seattlechildrens.org/
Working Group Organizers:
Benjamin Wilfond, MD
Paul Steven Miller, JD
Douglas Diekema, MD, MPH
Denise Dudzinski, PhD, MTS
Sara Goering, PhD